San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Aguado JM, REIPI Network.

Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D plus /R- solid organ transplant recipients

TRANSPLANT INFECTIOUS DISEASE 2015. 17(5): 637-646. Nº de citas: 15

[doi:10.1111/tid.12417]

de Egea V, Muñoz P, Valerio M, de Alarcón A, Lepe JA, Miró JM, Gálvez-Acebal J, García-Pavía P, Navas E, Goenaga MA, Fariñas MC, Vázquez EG, Marín M, Bouza E.

Characteristics and Outcome of Streptococcus pneumoniae Endocarditis in the XXI Century A Systematic Review of 111 Cases (2000-2013)

Medicine 2015. 94(39): . Nº de citas: 33

[doi:10.1097/MD.0000000000001562]

Blanco JR, Arroyo-Manzano D, Rojas-Liévano JF, Crespo M, Bravo I, Pasquau J, Garcia Del Toro M, Herrero C, Rivero A, Moreno S, Llibre JM.

The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not Influenced by Age

AIDS RESEARCH AND HUMAN RETROVIRUSES 2015. 31(9): 893-897. Nº de citas: 4

[doi:10.1089/aid.2015.0016]

Falcon A, Cuevas MT, Rodriguez-Frandsen A, Reyes N, Pozo F, Moreno S, Ledesma J, Martínez-Alarcón J, Nieto A, Casas I.

CCR5 deficiency predisposes to fatal outcome in influenza virus infection

JOURNAL OF GENERAL VIROLOGY 2015. 96(8): 2074-2078. Nº de citas: 42

[doi:10.1099/vir.0.000165]

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA, HIV-CAUSAL Collaboration.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study

The lancet. HIV 2015. 2(8): 335-343. Nº de citas: 37

[doi:10.1016/S2352-3018(15)00108-3]

Llibre JM, Rivero A, Rojas JF, Garcia Del Toro M, Herrero C, Arroyo D, Pineda JA, Pasquau J, Masiá M, Crespo M, Blanco JR, Moreno S.

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes

ANTIVIRAL RESEARCH 2015. 120: 79-84. Nº de citas: 11

[doi:10.1016/j.antiviral.2015.05.001]

Díaz L, Martínez-Bonet M, Sánchez J, Fernández-Pineda A, Jiménez JL, Muñoz E, Moreno S, Álvarez S, Muñoz-Fernández MÁ.

Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-kappa B-dependent mechanism

SCIENTIFIC REPORTS 2015. 5: 12442-12442. Nº de citas: 44

[doi:10.1038/srep12442]

Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM, Januskevica I, Gronborg-Laut K, Lundgren JD, Cozzi-Lepri A, EuroSIDA in EuroCOORD.

HIV resistance testing and detected drug resistance in Europe

AIDS 2015. 29(11): 1379-1389. Nº de citas: 12

[doi:10.1097/QAD.0000000000000708]

Martínez-Bonet M, Clemente MI, Serramía MJ, Moreno S, Muñoz E, Muñoz-Fernández MA.

Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells::a possibility for HIV-1 paediatric patients?

Journal of virus eradication 2015. 1(3): 148-152. Nº de citas: 4

May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte Ad, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA.

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2015. 69(3): 348-354. Nº de citas: 34

[doi:10.1097/QAI.0000000000000603]

Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM, OLE/RIS-EST13 Study Group.

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

LANCET INFECTIOUS DISEASES 2015. 15(7): 785-792. Nº de citas: 121

[doi:10.1016/S1473-3099(15)00096-1]

Aldámiz-Echevarría T, González-García J, Von Wichmann MA, Crespo M, López-Aldeguer J, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Bellón JM, Montes M, Berenguer J.

Association of baseline CD4+cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients

ANNALS OF HEPATOLOGY 2015. 14(4): 464-469. Nº de citas: 1

[doi:10.1016/S1665-2681(19)31167-6]

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S.

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

LANCET INFECTIOUS DISEASES 2015. 15(7): 775-784. Nº de citas: 103

[doi:10.1016/S1473-3099(15)00097-3]

Norman FF, Monge-Maillo B, Perez-Molina JA, de Ory F, Franco L, Sánchez-Seco MP, López-Vélez R.

Lymphadenopathy in Patients With Chikungunya Virus Infection Imported From Hispaniola: Case Reports

JOURNAL OF TRAVEL MEDICINE 2015. 22(4): 272-275. Nº de citas: 3

[doi:10.1111/jtm.12204]

Abad-Fernández M, Dronda F, Moreno A, Casado JL, Pérez-Elías MJ, Quereda C, Moreno S, Vallejo A.

Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-alpha/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2015. 69(3): 286-290. Nº de citas: 3

[doi:10.1097/QAI.0000000000000608]

Vázquez-Castellanos JF, Serrano-Villar S, Latorre A, Artacho A, Ferrús ML, Madrid N, Vallejo A, Sainz T, Martínez-Botas J, Ferrando-Martínez S, Vera M, Dronda F, Leal M, Del Romero J, Moreno S, Estrada V, Gosalbes MJ, Moya A.

Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals

MUCOSAL IMMUNOLOGY 2015. 8(4): 760-772. Nº de citas: 179

[doi:10.1038/mi.2014.107]

Boggild AK, Esposito DH, Kozarsky PE, Ansdell V, Beeching NJ, Campion D, Castelli F, Caumes E, Chappuis F, Cramer JP, Gkrania-Klotsas E, Grobusch MP, Hagmann SH, Hynes NA, Lim PL, López-Vélez R, Malvy DJ, Mendelson M, Parola P, Sotir MJ, Wu HM, Hamer DH, GeoSentinel Surveillance Network.

Differential Diagnosis of Illness in Travelers Arriving From Sierra Leone, Liberia, or Guinea: A Cross-sectional Study From the GeoSentinel Surveillance Network

ANNALS OF INTERNAL MEDICINE 2015. 162(11): 757-764. Nº de citas: 31

[doi:10.7326/M15-0074]

Brunetta J, Moreno Guillén S, Antinori A, Yeni P, Wade B, Johnson M, Shalit P, Ebrahimi R, Johnson B, Walker I, De-Oertel S.

Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH 2015. 8(3): 257-267. Nº de citas: 13

[doi:10.1007/s40271-015-0123-2]